To read the full story, subscribe or sign in.

RXI-109 shows promising results in phase I/II study in NVAMD

Aug. 2, 2018

No Comments

BioWorld Science Ocular

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 16, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Upgrade your daily dose of biopharma and medtech news

RXI-109 shows promising results in phase I/II study in NVAMD